Budd-Chiari syndrome primary prevention: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Budd-Chiari syndrome}} {{CMG}}; {{AE}} {{PleaseHelp}} ==Overview== ==Primary Prevention== ==References== {{reflist|2}} Category:Gastroenterology Categor...")
 
No edit summary
 
(5 intermediate revisions by one other user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Budd-Chiari syndrome}}
{{Budd-Chiari syndrome}}
{{CMG}}; {{AE}}
{{CMG}}; {{AE}}{{Mazia}}
 
{{PleaseHelp}}


==Overview==
==Overview==
Measures for the [[primary prevention]] of Budd-Chiari syndrome include effective management of predisposing conditions, [[chronic]] [[anticoagulation]] in patients with underlying [[Hypercoagulable state|hypercoagulable disorder]], treat [[patients]] with an underlying [[Myeloproliferative disease|myeloproliferative disorder]] with [[aspirin]] and [[hydroxyurea]] rather than [[anticoagulants]] such as [[warfarin]].


==Primary Prevention==
==Primary Prevention==
Measures for the [[primary prevention]] of Budd-Chiari syndrome include:<ref name="pmid26494427">{{cite journal |vauthors=Goel RM, Johnston EL, Patel KV, Wong T |title=Budd-Chiari syndrome: investigation, treatment and outcomes |journal=Postgrad Med J |volume=91 |issue=1082 |pages=692–7 |year=2015 |pmid=26494427 |doi=10.1136/postgradmedj-2015-133402 |url=}}</ref><ref name="pmid19652186">{{cite journal |vauthors=Darwish Murad S, Plessier A, Hernandez-Guerra M, Fabris F, Eapen CE, Bahr MJ, Trebicka J, Morard I, Lasser L, Heller J, Hadengue A, Langlet P, Miranda H, Primignani M, Elias E, Leebeek FW, Rosendaal FR, Garcia-Pagan JC, Valla DC, Janssen HL |title=Etiology, management, and outcome of the Budd-Chiari syndrome |journal=Ann. Intern. Med. |volume=151 |issue=3 |pages=167–75 |year=2009 |pmid=19652186 |doi= |url=}}</ref>
*Effective treatment of predisposing conditions
*[[Anticoagulation|Chronic anticoagulation]] in patients with underlying [[Hypercoagulable states|hypercoagulable disorder]]
*Treat patients with an underlying [[Myeloproliferative disease|myeloproliferative disorder]] with [[aspirin]] and [[hydroxyurea]] rather than [[anticoagulants]] such as [[warfarin]].


==References==
==References==

Latest revision as of 21:36, 1 December 2017

Budd-Chiari syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Budd-Chiari syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Budd-Chiari syndrome primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Budd-Chiari syndrome primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Budd-Chiari syndrome primary prevention

CDC on Budd-Chiari syndrome primary prevention

Budd-Chiari syndrome primary prevention in the news

Blogs on Budd-Chiari syndrome primary prevention

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Budd-Chiari syndrome primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mazia Fatima, MBBS [2]

Overview

Measures for the primary prevention of Budd-Chiari syndrome include effective management of predisposing conditions, chronic anticoagulation in patients with underlying hypercoagulable disorder, treat patients with an underlying myeloproliferative disorder with aspirin and hydroxyurea rather than anticoagulants such as warfarin.

Primary Prevention

Measures for the primary prevention of Budd-Chiari syndrome include:[1][2]

References

  1. Goel RM, Johnston EL, Patel KV, Wong T (2015). "Budd-Chiari syndrome: investigation, treatment and outcomes". Postgrad Med J. 91 (1082): 692–7. doi:10.1136/postgradmedj-2015-133402. PMID 26494427.
  2. Darwish Murad S, Plessier A, Hernandez-Guerra M, Fabris F, Eapen CE, Bahr MJ, Trebicka J, Morard I, Lasser L, Heller J, Hadengue A, Langlet P, Miranda H, Primignani M, Elias E, Leebeek FW, Rosendaal FR, Garcia-Pagan JC, Valla DC, Janssen HL (2009). "Etiology, management, and outcome of the Budd-Chiari syndrome". Ann. Intern. Med. 151 (3): 167–75. PMID 19652186.

Template:WS Template:WH